Bristol Myers Squibb gets FDA nod for Opdivo + Yervoy to treat liver cancer

This article was originally published here

The FDA accelerated approval was based on Opdivo + Yervoy’s overall response rate and duration of response in the cohort of the phase 1/2 CheckMate -040 trial. Around

The post Bristol Myers Squibb gets FDA nod for Opdivo + Yervoy to treat liver cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply